Sugi Predict

Sugi Predict / Compounds / SCHEMBL31537

SCHEMBL31537

SCHEMBL31537

O=S(=O)(Cl)c1cccc2cncc(F)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 12/20 0.47
▸ ROCK1 Q13464 12/20 0.47
▸ PRKCD Q05655 3/20 0.47
▸ PLK4 O00444 2/20 0.47
▸ MARK3 P27448 2/20 0.47
▸ PRKAA1 Q13131 2/20 0.47
▸ PKN2 Q16513 2/20 0.47
▸ MARK2 Q7KZI7 2/20 0.47
▸ AURKB Q96GD4 2/20 0.47
▸ PRKD2 Q9BZL6 2/20 0.47
▸ NQO2 P16083 1/20 0.47
▸ MAP2K3 P46734 1/20 0.47
▸ CDK9 P50750 1/20 0.47
▸ PRKAG1 P54619 1/20 0.47
▸ PKN1 Q16512 1/20 0.47
▸ MAP4K3 Q8IVH8 1/20 0.47
▸ TAOK3 Q9H2K8 1/20 0.47
▸ PRKACA P17612 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL28700199 0.98 ROCK2 (0.46) ROCK2ROCK1PRKCDPLK4MARK3
Hydrochloric Acid SCHEMBL999448 0.98 ROCK2 (0.47) ROCK2ROCK1PRKCDPLK4MARK3
Bromide SCHEMBL28709695 0.98 ROCK2 (0.46) ROCK2ROCK1PRKCDPLK4MARK3
Sulfuric Acid SCHEMBL28657307 0.95 ROCK2 (0.45) ROCK2ROCK1PRKCDPLK4MARK3
Formic Acid SCHEMBL28686548 0.93 ROCK2 (0.43) ROCK2ROCK1PRKCDPLK4MARK3
SCHEMBL28481339 0.86 ROCK2 (0.41) ROCK2ROCK1PRKCDPLK4MARK3
SCHEMBL14990455 0.85 ROCK2 (0.48) ROCK2ROCK1PRKCDPLK4MARK3
SCHEMBL12925684 0.83 ROCK2 (0.50) ROCK2ROCK1PRKCDPLK4MARK3
SCHEMBL28644536 0.83 ROCK2 (0.47) ROCK2ROCK1PRKCDPLK4MARK3
SCHEMBL998049 0.83 ROCK2 (0.47) ROCK2ROCK1PRKCDPLK4MARK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113582926-B Synthesis method of 4-fluoroisoquinoline-5-sulfonyl chloride or pharmaceutically acceptable salt thereof 安徽有吉医药科技有限公司 2022-03-01 — — CN claimed
CN-113582926-A Synthesis method of 4-fluoroisoquinoline-5-sulfonyl chloride or pharmaceutically acceptable salt thereof 安徽有吉医药科技有限公司 2021-11-02 — — CN claimed
EP-1852421-B1 PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF KOWA CO (JP) 2011-05-04 — — EP claimed
US-7872136-B2 Process for production of 4-fluoroisoquinoline-5-sulfonyl halide or salt thereof KOWA CO., LTD. (JP) 2011-01-18 — — US claimed
US-20090209765-A1 PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF KOWA CO., LTD. (JP) 2009-08-20 — — US claimed
EP-1852421-A1 PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF Kowa Company, Ltd. (JP) 2007-11-07 — — EP claimed
CN-113227054-B ROCK kinase inhibitors 切尔韦洛治疗有限责任公司 2025-04-11 — — CN disclosed
CN-116143713-B 1, 4-Diazacycloheptane series derivatives and preparation method thereof 嘉兴和剂药业有限公司 2025-03-28 — — CN disclosed
CN-118580192-A Preparation method of chiral intermediate of drug for treating ocular hypertension 安徽峆一药业股份有限公司 2024-09-03 — — CN disclosed
EP-3877364-B1 ROCK KINASE INHIBITORS Cervello Therapeutics LLC (US) 2024-08-21 — — EP disclosed
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 — — US disclosed
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 — — US disclosed
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors CERVELLO THERAPEUTICS, LLC. (US) 2024-02-27 — — US disclosed
US-20070179127-A1 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2007-08-02 — — US disclosed
EP-0885888-B1 ISOQUINOLINE DERIVATIVES AND DRUGS HIDAKA HIROYOSHI DR (JP) 2003-08-13 — — EP disclosed
US-6323217-B2 CARDIOVASCULAR DISORDERS ADIR ET COMPAGNIE (FR) 2001-11-27 — — US disclosed
US-20010034352-A1 Piperidine-4 sulphonamide compounds LES LABORATOIRES SERVIER (FR) 2001-10-25 — — US disclosed
EP-1074545-A1 ISOQUINOLINESULFONAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT Hidaka, Hiroyoshi (JP) 2001-02-07 — — EP disclosed
US-6153608-A Isoquinoline derivatives and drugs NIPPON SHINYAKU CO., LTD. (JP) 2000-11-28 — — US disclosed
EP-0885888-A1 ISOQUINOLINE DERIVATIVES AND DRUGS NIPPON SHINYAKU COMPANY, LIMITED (JP) 1998-12-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034352-A1 Piperidine-4 sulphonamide compounds KDR, GLS, FLT1 ROCK2 3943/4885ROCK1 3820/4885PRKCD 536/4885
US-20070179127-A1 Sulfonamide compound MYLK, MYLK2, MYLK3 ROCK2 332/4885ROCK1 240/4885PRKCD 975/4885
US-11912719-B2 Substituted isoquinolines as rock kinase inhibitors ROCK1, ROCK2, CIT ROCK2 2/4885ROCK1 1/4885PRKCD 235/4885
US-20090209765-A1 PROCESS FOR PRODUCTION OF 4-FLUOROISOQUINOLINE-5-SULFONYL HALIDE OR SALT THEREOF SALL4, STS, SFPQ ROCK2 3563/4885ROCK1 4159/4885PRKCD 3600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.